BIOMAT Database Logo BIOMAT Database Logo

The 9L rat brain tumor: description and application of an animal model. 1981

M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker

Animal models allow determination of tumor response to anticancer agents under various experimental conditions. The chemically induced 9L rat brian tumor has been developed as both in vivo and in vitro models. Animal survival, clonogenic cell survival, and tumor growth delay provide means to measure the effectiveness of treatment modalities in this tumor model. Monolayer cultures, multicellular spheroid cultures, brain tumors, and flank tumors have been used to study the influence of different biological entities of the 9L model on the response to treatment with radiation and/or BCNU (1,3-bis (2-chloroethyl)-1-nitrosourea).

UI MeSH Term Description Entries
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
Intracerebral chemotherapy in the 9L rat brain tumor model.
November 1992, Journal of neuro-oncology,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
Combination chemotherapy for the 9L rat brain tumor model system.
March 1982, Cancer treatment reports,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
Hematoporphyrin derivative photoradiation therapy of the rat 9L gliosarcoma brain tumor model.
January 1984, Lasers in surgery and medicine,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
Effect of spirogermanium and radiation therapy on the 9L rat brain tumor model.
January 1988, NCI monographs : a publication of the National Cancer Institute,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
Combination of radiation therapy and intracranial bleomycin in the 9L rat brain tumor model.
May 1990, International journal of radiation oncology, biology, physics,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
Post-treatment kinetics of BCNU in a 9L rat brain tumor model.
January 1981, Neurologia medico-chirurgica,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.
February 1993, Journal of neuro-oncology,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions.
January 1994, Journal of neuro-oncology,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
[Effect of perfluorochemicals on BCNU chemotherapy in a 9L rat brain tumor model].
October 1982, Neurologia medico-chirurgica,
M Weizsaecker, and D F Deen, and M L Rosenblum, and T Hoshino, and P H Gutin, and M Barker
Combination of aziridinylbenzoquinone and cis-platinum with radiation therapy in the 9L rat brain tumor model.
June 1993, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!